Raw materials qualification is the process of verifying that incoming materials meet predefined specifications before they enter the manufacturing process. FDA’s CGMP regulations (21 CFR Parts 211 and 820) and ISO 13485 both require documented incoming acceptance activities, supplier qualification, and identity testing for materials used in regulated products. A compliant raw materials qualification program includes written specifications for every material, a defined incoming inspection procedure, laboratory testing where required, and a documented decision to accept or reject each lot. Materials released without proper qualification are one of the more consistent sources of FDA Form 483 citations in pharmaceutical and medical device manufacturing.

What is raw materials qualification?

Raw materials qualification covers two related but distinct activities. The first is supplier qualification: the process of evaluating and approving a supplier before their materials enter the supply chain. The second is incoming inspection and acceptance: the per-lot testing and review that happens when a shipment arrives at the facility.

In pharmaceutical manufacturing, “raw materials” typically refers to active pharmaceutical ingredients (APIs), excipients, processing aids, primary packaging materials, and cleaning agents that contact the product or primary container. In medical device manufacturing, raw materials include component materials, sub-assemblies, chemicals used in processing, and any material that becomes part of the finished device.

Supplier quality management and incoming materials acceptance are two sides of the same program. A strong supplier qualification program reduces the testing burden at incoming inspection. A weak supplier program increases the testing required at the receiving dock to compensate for unknown supplier capability.

Regulatory requirements: FDA CGMP (21 CFR Part 211)

For pharmaceutical manufacturers, 21 CFR Part 211 Subpart E covers the control of components and drug product containers and closures. The key requirements:

Section 211.80 — General requirements. Written procedures describing the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components must be available and followed.

Section 211.82 — Receipt and storage. Components must be stored under quarantine until tested or examined and released. Each shipment must be examined for identity, condition of containers, and any evidence of contamination.

Section 211.84 — Testing and approval. At least one test for identity must be conducted on each lot of each component before use. This is a hard requirement: FDA does not accept manufacturer certificates of analysis (CoA) as a substitute for identity testing unless a validation study has been conducted proving that the supplier’s CoA is reliable for that specific material and supplier.

Section 211.86 — Use of approved components. Only components that have been released by the quality unit may enter manufacturing. This means the release decision must be documented in the quality system before the material moves to production.

Section 211.87 — Retesting of approved components. Components that have been in storage for a defined period must be retested for conformance before use. The retesting intervals should be based on stability data for the specific material.

Regulatory requirements: FDA QMSR (21 CFR Part 820)

For medical device manufacturers, the Quality Management System Regulation (21 CFR Part 820) addresses incoming materials through purchasing controls (Section 820.50) and receiving, incoming inspection, and testing (Section 820.80).

Section 820.80(b) requires that incoming product not be used or processed until it has been inspected or otherwise verified as conforming to specified requirements. The methods and extent of incoming inspection must be based on risk, with higher-risk components receiving more intensive inspection.

Critically, the regulation allows manufacturers to use supplier data as part of their incoming inspection approach, provided they have established through supplier qualification that the supplier’s data is reliable. This creates a tiered incoming inspection model: fully qualified suppliers with strong track records may support a reduced incoming testing regime, while new or lower-performing suppliers receive more intensive lot-level testing.

ISO 13485 requirements for incoming materials

ISO 13485 Section 7.4.3 covers verification of purchased product. Manufacturers must establish and implement inspection or other activities necessary to ensure that purchased product meets specified purchase requirements. The section explicitly states that the type and extent of inspection must be based on the results of supplier evaluation and the risk associated with the purchased product.

ISO 13485 requires that the basis for the incoming inspection approach, including the rationale for reduced inspection where applied, be documented. If a manufacturer has qualified a supplier to the point where they rely heavily on supplier CoA data without independent testing, that qualification basis must be documented and periodically reviewed.

Section 7.4.1 establishes the broader supplier evaluation and selection framework. Suppliers must be evaluated on their ability to provide product that meets requirements. The results of evaluations and follow-up actions must be recorded.

Identity testing: the requirement that many companies miss

Identity testing is the test that confirms a material is what the label says it is, typically using a physical or chemical method that is specific to the material. For pharmaceutical raw materials under 21 CFR Part 211.84, FDA requires at least one identity test on every incoming lot without exception.

FDA has repeatedly issued 483 observations to pharmaceutical manufacturers for relying solely on supplier certificates of analysis as the identity test. A CoA is not an identity test; it is a document. The regulations require an independent test performed on the material received, not a review of a document describing tests performed elsewhere.

Common identity test methods include:

• Infrared spectroscopy (IR/FTIR) for organic materials and polymers
• High-performance liquid chromatography (HPLC) for APIs and complex chemicals
• Wet chemical tests specified in pharmacopeial monographs (USP, EP, JP)
• Near-infrared (NIR) spectroscopy with validated reference libraries

For medical device materials under 21 CFR Part 820, identity testing is not explicitly required for every lot in the same way as pharmaceutical CGMP. But the risk-based incoming inspection requirement still demands that manufacturers define what verification is appropriate for critical materials. For a material whose identity is critical to device safety, an identity test on incoming lots is consistent with a risk-based approach.

Specifications: the foundation of incoming inspection

No incoming inspection program can function without written specifications. A specification defines what the material must be in order to be accepted. Incoming inspection is the process of comparing what arrived to what the specification requires.

A complete raw material specification typically includes:

• Material name, grade, and intended use
• Physical properties (appearance, particle size, density, viscosity as applicable)
• Chemical identity (assay, specific tests, pharmacopeial monograph reference)
• Purity limits (related substances, heavy metals, water content as applicable)
• Microbiological limits where applicable
• Packaging and labeling requirements
• Storage conditions and retest interval
• Approved supplier list reference

Specifications must be established before the first lot of a material is released for use, not written retroactively to match what arrived. FDA inspectors look for evidence that specifications were approved through the quality system before manufacturing began, not created after the fact.

The approved supplier list and incoming inspection

The supplier quality management program provides the context within which incoming inspection operates. Every material in the incoming inspection program should have a defined list of approved suppliers. Materials from unapproved suppliers, or from approved suppliers for unapproved materials, should not enter the incoming release process until a supplemental qualification review is completed.

The approved supplier list integrates directly with incoming inspection in two ways:

First, it defines who may supply each material. If a CoA arrives from a supplier not on the approved list for that material, the shipment should be quarantined and the supplier qualification team notified before the lot moves through the inspection process.

Second, the supplier’s qualification tier influences the intensity of incoming inspection. A fully qualified supplier with a consistent track record of conforming material may support a skip-lot testing approach, where not every lot is tested to the full specification. A provisional supplier, or one with recent nonconformances, requires full lot testing until their performance is re-established.

Sampling plans for incoming inspection

Sampling plans define how many units from a lot are selected for inspection and what the accept/reject criteria are. A statistically sound sampling plan gives the inspection program a defensible basis for concluding that a lot meets specification based on the sample tested.

Common sampling frameworks used in regulated industries include ANSI/ASQ Z1.4 for attribute sampling (pass/fail tests) and ANSI/ASQ Z1.9 for variable sampling (numerical measurements). Many companies also use risk-based sampling plans that allocate inspection intensity based on the criticality of the material and the supplier’s historical performance.

The sampling plan must be written into the incoming inspection procedure and reviewed by quality assurance. Ad hoc decisions about how many samples to take are not acceptable for regulated materials.

Quarantine, hold, and disposition

Every incoming lot must go through a defined quarantine and disposition process. Quarantine prevents materials from entering manufacturing before the inspection decision is made. Disposition is the quality unit’s documented decision to accept or reject the lot.

Physical quarantine means the material is stored in a separate location, or is physically labeled and segregated, in a way that prevents unauthorized use. Electronic quarantine, enforced through a QMS system that prevents production work orders from drawing on uninspected inventory, is also acceptable when the system has been validated for this purpose.

The disposition decision must be made by a qualified quality representative and documented with a signature and date. A lot that fails incoming inspection must be formally rejected and either returned to the supplier or destroyed under documented procedures. Rejected materials must not be accessible to production.

Documentation and records

FDA and ISO 13485 require that incoming inspection records be maintained for a defined retention period. Complete incoming inspection records include:

• Supplier and lot identification
• Date received
• Quantity received
• Inspection or test results
• Reference to the relevant specification
• Name or signature of the inspector
• Disposition decision (accept or reject) and the name or signature of the quality unit representative who made it

These records must be linked to the manufacturing batch records that use the material, creating traceability from the incoming lot through to the finished product. If a problem is discovered in a finished product, this traceability chain allows the quality team to identify all batches that used the same incoming lot.

How a QMS platform supports raw materials qualification

Managing incoming inspection through paper-based forms or disconnected spreadsheets creates traceability gaps and slows the release process. A modern QMS integrates incoming inspection with the broader supplier qualification and materials management program.

Cloudtheapp’s platform handles the full incoming materials workflow: from supplier approval status verification at the point of receipt, through the structured inspection record, laboratory test entry, and disposition decision, to final release and linkage to the inventory record. Each step in the process is tracked in real time, and the system prevents materials from moving to production without a completed release decision in the record.

The platform’s supplier qualification module maintains the approved supplier list, supplier performance scores, and audit history. When incoming inspection identifies a nonconformance, the system routes a nonconforming material record to the appropriate quality reviewer and links it to the supplier’s performance data. If the nonconformance triggers a supplier corrective action request, the SCAR record is created from within the incoming inspection record with no re-entry required.

For companies that have experienced FDA 483 observations related to incoming inspection, particularly around identity testing documentation or missing lot release records, a structured QMS platform closes the documentation gaps that manual processes leave open. See how Cloudtheapp manages raw materials incoming acceptance at cloudtheapp.com/demo.

Conclusion

Raw materials qualification is a regulatory requirement and a quality system foundation. FDA’s identity testing requirement, the approved supplier list, written specifications, documented sampling plans, and formal disposition records are not optional elements of the program. They are the components that FDA inspectors and ISO auditors check first when reviewing a company’s incoming materials controls. Companies that build these components correctly, and support them with a QMS that enforces the process, produce consistent documentation and avoid the inspection findings that plague manufacturers who manage incoming inspection informally.

This post created by and appeared first on Cloudtheapp